Background. The endothelium possesses the ability to modulate vascular tone by the release of vasodilators and vasoconstrictors, among them endothelium-derived relaxing factor (EDRF) and endothelin (ET). Abnormalities in EDRF generation have been demonstrated in various cardiovascular pathophysiological states. Moreover, a twofold increase in plasma ET concentration was reported in these disease states. Recent in vitro studies have suggested the interaction between these two endotheliumderived substances, suggesting that imbalance between the two may contribute to alternation in vascular tone characteristic of these disease states. Thus, the hypothesis of this study was that inhibition of endogenous EDRF will enhance the vasoconstrictor response to a twofold increase in plasma ET concentrations.
basal systemic and regional vascular resistances. [10] [11] [12] Investigators also suggest that abnormalities in EDRF generation may contribute to the abnormal vascular responses and pathophysiology of such cardiovascular disease states as atherosclerotic vascular disease, essential hypertension, and congestive heart failure.3 '13-17 ET is a recently described endothelial-derived vasoconstrictor peptide, whose vasoconstrictor actions are opposed by EDRF. [18] [19] [20] [21] [22] Increasing evidence indicates that, in addition to its known role as an autacoid, ET is present in the plasma of normal humans and animals. 23, 24 The importance of its presence in the circulation is underscored by increased plasma concentrations of ET in disorders of cardiovascular, pulmonary, and renal dysfunction. Specifically, plasma ET concentrations have been reported to be increased twofold in atherosclerotic vascular disease,25 congestive heart failure, 26 and essential and pulmonary hypertension.27 '28 We have recently reported that synthetic ET, administered at doses that approximate these pathophysiological concentrations, results in a significant increase in systemic and renal vascular resistances in the absence of alterations in arterial pressure and pulmonary and coronary vascular resistances. 29 When all these observations are taken together, cardiovascular disease states may be characterized by an attenuated release of EDRF, whereas the release of ET is augmented. Therefore, a functional mechanism of the increased vascular tone characteristic of these disease states may be an imbalance between these endothelial-derived vasoconstrictor and vasodilator factors.
To further investigate the modulating actions of the endogenous EDRF system on ET-mediated systemic and regional vasoconstriction, the current study was designed to test the hypothesis that inhibition of endogenous EDRF will enhance the vasoconstrictor response to exogenous ET. To test this hypothesis, systemic, coronary, pulmonary, and renal vascular responses were determined in response to pathophysiological concentrations of ET in three groups of anesthetized dogs receiving ET-1 at a dose to double plasma ET (group 1), ET with L-NMMA to inhibit EDRF generation (group 2), and L-NMMA alone (group 3) to evaluate the action of EDRF inhibition alone.
Methods
Acute experiments were conducted in three groups of anesthetized dogs (weight, 18-25 kg). Each dog was fasted overnight and tap water was available ad libitum. Dogs were anesthetized with sodium pentobarbital (30 mg/kg), with additional anesthetic given as needed to maintain a constant level of anesthesia. An endotracheal tube was inserted, and the dog was ventilated with a Harvard respirator (Harvard Apparatus Co., Inc., South Natick, Mass.), using room air throughout the experiment. Respiratory rate and tidal volume were adjusted to body weight to maintain physiologically normal blood gases. Femoral arteries and veins were cannulated with polyethylene catheters for monitoring mean arterial pressure (MAP) and intravenous infusions of saline L-NMMA and ET, respectively.
The heart was exposed through a left thoracotomy along the fourth intercostal space. The pericardium was opened, and a 1-cm segment of the proximal left circumflex coronary artery was dissected free from the surrounding tissue. A calibrated electromagnetic flow probe was positioned on the proximal circumflex coronary artery and connected to a flowmeter (model FM 5010, Carolina Medical Electronics, Inc., King, N.C.) for measurement of coronary blood flow (CBF). A flow-directed, balloon-tipped thermodilution catheter (model 93A-131, 7F, American Edwards Laboratories, Inc.) was advanced from the isolated right external jugular vein through the right cardiac chamber and positioned in the pulmonary artery for measurement of right atrial (RAP), pulmonary arterial (PAP), and pulmonary arterial wedge pressures (PAWP). The left kidney was exposed through a flank incision, permitting cannulation of the ureter for urine collection and placement of a calibrated electromagnetic flow probe around the left renal artery for measurement of renal blood flow (RBF). The flow probe was connected to a flowmeter as described above for measurement of CBF.
Cardiac output (CO) was determined as an average of four measurements by the thermodilution technique with a CO computer (model 9510-A, American Edwards Laboratories, Inc.). Continuous electrocardiographic monitoring was performed throughout the ex-flows and arterial blood pressures were recorded on a Model 2200 Gould strip recorder.
Experimental Protocol
After an equilibration period of 1 hour after completion of surgical procedures, and during which saline infusions at 1 ml/min were started, 30-minute baseline control clearance was performed. At the midpoint of each clearance period, hemodynamic parameters were measured and arterial blood was collected for subsequent measurement of ET.
After completion of these baseline clearances, ET-1 (Peninsula, Belmont, Calif.) was infused intravenously at 1 ml/min in dogs in the experimental group 1 (n=5) at 2.5 ng/kg/min. This dose was chosen to double circulating ET based on previous studies.29 Group 2 (n=6) received L-NMMA, a competitive inhibitor of EDRF generation, at a continuous rate of 50 ,ug/kg/min and ET-1 at 2.5 ng/kg/min. Group 3 (n=6) received L-NMMA alone at 50 ,g/kg/min. The drugs were infused for 120 minutes, and a clearance was obtained during the last 30 minutes of the infusion, with measurements and collections as described above for the control periods. At the end of the L-NMMA infusion (group 3), L-arginine was administered (300 mg/kg i.v.), and hemodynamics were assessed immediately.
Plasma ET was determined by ET-1,2[125I] assay system from Amersham. Blood was drawn from dogs into tubes containing chilled potassium ethylenediaminetetraacetic acid and immediately placed on ice until being centrifuged at 4°C. Plasma was separated and frozen at -20°C until assay. Before radioimmunoassay, plasma was acidified with 0.5% trifluoroacetic acid (TFA). C8 Bond Elut cartridges were washed with 4 ml of methanol and 4 ml of water to extract the plasma. After the plasma was applied, cartridges were washed with 2 ml of normal saline and 6 ml of water. ET was eluted from the cartridges with 2 ml of 90% methanol in 1% TFA and was then dried and reconstituted for radioimmunoassay. The recovery of the extraction procedure was 81% as determined by addition of synthetic ET to plasma; interassay and intra-assay variations were 9% and 5%, respectively. Hemodynamic data included MAP, RAP, PAWP, PAP, RBF, CBF, and CO. Calculated parameters included 1) systemic vascular resistance: SVR=I(MAP-RAP)/CO; 2) pulmonary vascular resistance: PVR=(PAP-PAWP)/CO; 3) renal vascular resistance: RVR=(MAP-RAP)/RBF; and 4) coronary vascular resistance: CVR= (MAP-RAP)/CBF.
Statistics
Data from all clearance periods were measured and expressed as mean+SEM. All data were analyzed by ANOVA and paired and unpaired t tests. Significance was accepted forp<0.05. Table 1 summarizes the cardiopulmonary and renal hemodynamics of the experimental groups. No statistical differences were observed between the experimental groups at baseline. In group 1, in which plasma ET doubled during exogenous ET administration (Figure 1 ), SVR increased (p<0.05), and HR and CO decreased (p<0.05). No effect periment for measurement of heart rate (HR). Blood In group 2, administration of ET with L-NMMA resulted in a similar increase in plasma ET, as was observed in group 1 with ET alone. Administration of ET with L-NMMA markedly increased MAP (p<0.05). This increase was significantly greater than with ET alone (Figure 2) . SVR, CVR, RVR, and PVR also increased (p<0.05), exceeding the increases that were observed in group 1 (Figure 2 ). CO mm Hg/ml/min; and PVR, 6.5+0.6 to 5.5 ±0.7 mm Hg/l/ min).
Results

Discussion
The current study was designed to investigate in the intact animal the modulating action of the endogenous EDRF system on ET-mediated systemic and regional vasoconstriction. The current study demonstrates that a doubling of circulating ET to mimic pathophysiological concentrations results in systemic and renal but not pulmonary or coronary vasoconstriction. In contrast, in the presence of inhibition of endogenous EDRF generation with L-NMMA, a similar increase in circulating ET mediates marked generalized vasoconstriction involving the systemic, renal, pulmonary, and coronary arterial circulations. These studies are consistent with the hypothesis that the endogenous EDRF system serves as a functionally important modulator of the vasoconstrictor actions of ET. [20] [21] [22] Repeated investigations have demonstrated that at pharmacological concentrations, ET is a potent coronary, renal, and systemic vasoconstrictor. '9 In addition to its role as a local autacoid, however, increasing evidence indicates that ET is present in the plasma of normal humans and animals.2324 The importance of its presence in the circulation is underscored by increased circulating concentrations in cardiovascular disease states. Specifically, circulating ET has been demonstrated to be increased threefold in congestive heart failure,26 twofold in essential and pulmonary hypertension,27,28 transplantation-associated hypertension,30 and atherosclerotic vascular disease. 25 The current study reconfirms and extends our recent investigations and demonstrates that a doubling of circulating concentration of ET results in significant vasoconstriction involving the renal and systemic but not the pulmonary and coronary circulation. 29 The current studies also confirm and extend recent reports from our laboratory and others that the endogenous EDRF system participates in basal regulation of systemic and regional vascular tone.10"'1 In response to continuous inhibition of EDRF generation by steady-state intravenous infusion of L-NMMA, SVR, RVR, and PVR but not CVR increased. Similar responses in SVR and RVR to ET were observed. A differential response, however, was observed in the pulmonary circulation, in which EDRF inhibition but not ET resulted in pulmonary vasoconstriction. This observation may suggest that in the lung, EDRF may play a more dominant role and contribute to the low vascular tone that characterizes the pulmonary circulation under basal conditions. These results are in accord with studies of Perrella et al,31 which demonstrated a major role for EDRF in the regulation of PVR in acute hypoxia and the report of impaired endothelium-dependent pulmonary vasodilatation in patients with end-stage lung disease and pulmonary hypertension.32 That this augmented vascular response is not a nonspecific potentiation by an L-NMMA-mediated increase in vascular tone is suggested by studies by Cavero and colleagues33; these studies demonstrated that in experimental heart failure in which SVR and RVR are increased, the vasoconstrictive response to exogenous ET is not enhanced.
The role of EDRF in modulating the vasoconstrictor response to ET may extend to norepinephrine. In studies in vitro, removal of the endothelium in isolated coronary arteries potentiated the vasoconstrictor action to norepinephrine. 34, 35 These investigators concluded that EDRF may be released by norepinephrine and attenuate active vasoconstriction. Furthermore, nitric oxide itself in vitro equally relaxes human arteries preconstricted with ET or norepinephrine.20 Thus, when the present and previous studies are taken together, a critical role for EDRF emerges as a functional modulator of endogenous local and circulating vasoconstrictors.
The current study reports for the first time the potentiating action in vivo of EDRF inhibition on ET-mediated vasoconstriction. Inhibition of endogenous EDRF by L-NMMA markedly enhanced the vasoconstrictor action of ET in all vascular beds. These responses were not associated with further increases in plasma ET. Luscher and colleagues20 have reported that in vitro, EDRF inhibited ET-induced contraction in normal human internal mammary arteries. These investigators speculated that inhibition of EDRF could sensitize vascular smooth muscle to the vasoconstrictor actions of ET and thus serve as a counter-regulatory mechanism to the local vasoconstrictor actions of ET. The current in vivo study is consistent with this speculation and demonstrates this concept in the regulation of systemic, coronary, renal, and pulmonary circulations.
In the present study, ET administration but not EDRF inhibition was associated with bradycardia. Because this decrease in HR was not accompanied by changes in MAP, ET may have a unique direct effect on the cardiac conduction system,36 or it may serve as a neuromodulator.37 CO decreased with both ET and L-NMMA but was not augmented with the combination, which suggests that the greater vasoconstriction achieved with the combination resulted from direct effects on the vascular bed.
The role of the endothelium in the pathophysiology of various vascular diseases has been suggested,3'5 specifically atherosclerotic vascular disease, congestive heart failure, and essential and pulmonary hypertension.1-6 Atherosclerotic vessels from animals and humans exhibit diminished EDRF release'13'14"6; a defect 1 in the endothelium to produce EDRF was also demonstrated in essential and pulmonary hypertension15,32 and congestive heart failure.17 Moreover, at least a twofold increase in plasma ET concentration has been reported in atherosclerotic vascular disease, congestive heart failure, and essential and pulmonary hypertension. [25] [26] [27] [28] Thus, these pathophysiological states are characterized by a blunted endothelial release of EDRF in association with an increase in circulating ET. One may speculate that such an imbalance between endothelium-dependent vasorelaxing and vasoconstricting factors, as was acutely produced experimentally in the current study, contributes to the systemic and regional vasoconstriction as observed in cardiovascular disease states. Such changes in endothelial function could promote arterial vasospasm and vascular occlusion.
Summary
The present study demonstrates that inhibition of endogenous EDRF by L-NMMA together with doubling of plasma ET concentration, as seen in disorders of the cardiovascular and pulmonary systems, results in systemic, coronary, pulmonary, and renal vasoconstriction. These results support a potential functional and pathophysiological role for the balance between endothelial-derived vasodilator and vasoconstrictor substances in the regulation of vascular tone.
